The September 2016 Political Declaration of the High-level Meeting on Antimicrobial Resistance (Resolution A/RES/71/3) called for the establishment of the Interagency Coordination Group on Antimicrobial Resistance (IACG), in consultation with the World Health Organization (WHO), the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (OIE). The IACG’s mandate is to provide practical guidance for approaches needed to ensure sustained effective global action to address antimicrobial resistance; and to report back to the UN Secretary-General in 2019. This includes making recommendations on how to better coordinate action across sectors and countries, as well as serving as a vehicle for building political momentum and future governance, and mobilising a broad base of stakeholders. The IACG is made up of representatives from the major UN and multi-sectoral agencies and a similar number of individual experts.
The IACG Secretariat, on behalf of the IACG, has launched a web-based consultation to solicit feedback on the discussion papers prepared by the IACG of their work to date.
As part of the consultation, the MPP submitted comments on the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
Access MPP comments on the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
Access all comments on the discussion paper
Access the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
More information about the Interagency Coordination Group on Antimicrobial Resistance (IACG)
MPP Publications
MPP comments on the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
1 July 2018
The September 2016 Political Declaration of the High-level Meeting on Antimicrobial Resistance (Resolution A/RES/71/3) called for the establishment of the Interagency Coordination Group on Antimicrobial Resistance (IACG), in consultation with the World Health Organization (WHO), the Food and Agriculture Organization (FAO), and the World Organisation for Animal Health (OIE). The IACG’s mandate is to provide practical guidance for approaches needed to ensure sustained effective global action to address antimicrobial resistance; and to report back to the UN Secretary-General in 2019. This includes making recommendations on how to better coordinate action across sectors and countries, as well as serving as a vehicle for building political momentum and future governance, and mobilising a broad base of stakeholders. The IACG is made up of representatives from the major UN and multi-sectoral agencies and a similar number of individual experts.
The IACG Secretariat, on behalf of the IACG, has launched a web-based consultation to solicit feedback on the discussion papers prepared by the IACG of their work to date.
As part of the consultation, the MPP submitted comments on the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
Access MPP comments on the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
Access all comments on the discussion paper
Access the discussion paper “Antimicrobial resistance: Invest in innovation and research, and boost R&D and access”
More information about the Interagency Coordination Group on Antimicrobial Resistance (IACG)
Contact Us
Press and Media
About Us
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 18 patent holders for 14 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, three oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.